
Latest News
Logo

Press release
Available in
English
The European Parliament has voted to give greater powers to the European Medicines Agency (EMA) to help it better manage public health crises and improve access to critical medicines and medical devices for consumers.
Press release
Available in
English
The EU institutions have struck a long overdue deal that will require Member States to carry out joint assessments of medicines and other health technologies for the EU market.
Press release
Available in
English
BEUC welcomes today’s European Commission decision that renders legally binding commitments by pharma company Aspen to reduce significantly the prices of certain anti-cancer drugs (by on average 73% in Europe for the next 10 years). The decision follows a Commission antitrust investigation opened in May 2017 into whether Aspen breached EU antitrust rules’ ban on dominant companies imposing unfair prices.
Press release
Available in
English
Today, the European Commission has unveiled a new plan to turn the tide against cancer. Unhealthy diets as well as overweight and obesity are significant risk factors for cancer. BEUC welcomes that the EU Commission wants to help prevent cancer by making healthy food choices easier for consumers. However, it is a disappointment that some measures on ending EU-funded ads for meat have been watered down in the plan’s final version.
Press release
Available in
English
The European Consumer Organisation (BEUC) welcomes the European Commission’s decision today to fine Teva and Cephalon 30 and 30.5 million euros respectively for agreeing not to market a cheaper generic version of Cephalon's drug for sleep disorders, modafinil, in Europe for six years. The “pay for delay” agreement, which the Commission has found to violate EU antitrust rules, allowed Cephalon to charge European patients and healthcare systems higher prices for the drug in the six year period before Teva finally marketed its generic alternative.
Press release
Available in
English
The EU Commission published its Pharmaceutical Strategy today, aiming to ensure patients timely access to safe and affordable treatment and to support medical innovation and pharma competitiveness. The Strategy brings momentum to effectively address medicine shortages and high prices, a long-standing issue in the EU.